

Informazione Regolamentata n. 0957-58-2025	Data/Ora Inizio Diffusione 22 Dicembre 2025 17:21:44	Euronext Milan
--	---	----------------

Societa' : DIASORIN

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio Vaccarone

Tipologia : 3.1

Data/Ora Ricezione : 22 Dicembre 2025 17:21:44

Data/Ora Inizio Diffusione : 22 Dicembre 2025 17:21:44

Oggetto : Publication of documents for the Shareholders' Meeting to be held on January 27, 2026

Testo del comunicato

See in attachment.

DIASORIN: PUBLICATION OF THE DOCUMENTS FOR THE SHAREHOLDERS' MEETING SCHEDULED ON JANUARY 27, 2026 IN ORDINARY AND EXTRAORDINARY SESSION

Saluggia, December 22, 2025 – In relation to the shareholders' meeting of DiaSorin S.p.A. (FTSE MIB: DIA) convened in ordinary and extraordinary session, in a single call on January 27 4, 2026, at 10:00 a.m. CET, it is announced that - in compliance with the applicable legal requirements – today the Company made available at its registered office, on its website (<https://int.diasorin.com>, Section "Company/Governance/Shareholders' Meeting/2025") and on the on the authorized central storage mechanism "eMarketStorage" (www.emarketstorage.com):

- the Explanatory Reports on the items on the agenda,
- the proxy forms pursuant section 125-*novies* and 135-*undecies* of Legislative Decree 58/1998.

The remaining documents related to the Shareholders' Meeting will be made available within the terms and according to the modalities set forth by the law.

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it

